


NB-004: 4-1BB Agonist Antibody



A best-in-class recombinant humanized antibody targeting 4-1BB (CD137) for advanced and metastatic solid tumors. This injectable therapeutic addresses a \$6B market opportunity with FDA IND approval and strong global patent protection.

NB-004: Best-in-Class 4-1BB Agonist Antibody



Immuno-Oncology Innovation

NB-004 is a best-in-class recombinant humanized antibody targeting 4-1BB (CD137) for advanced and metastatic solid tumors. This injectable therapeutic addresses a **\$6B market opportunity** with **FDA IND approval** and strong global patent protection.

The 4-1BB pathway represents a validated immuno-oncology target for T cell activation, but previous clinical attempts have been limited by dose-limiting hepatotoxicity. NB-004's unique mechanism addresses this critical safety challenge while maintaining potent anti-tumor activity.

Unique Epitope Binding

Overlaps with endogenous 4-1BB ligand binding site, mimicking natural T cell activation

Balanced Activation

Optimal T cell stimulation while blocking excessive CD137 ligand-mediated activation


Clinical-Stage Safety

Designed to avoid hepatotoxicity that limited previous 4-1BB agonist development

NB-004: Optimized T Cell Activation with Superior Safety

Biomimetic Mechanism of Action

NB-004 binds to a **unique epitope of 4-1BB that overlaps with the endogenous 4-1BB ligand**, creating a biomimetic activation pattern. This binding paradigm mimics natural CD137 ligand activity for T cell activation while simultaneously blocking excessive ligand-mediated stimulation, achieving optimal 4-1BB axis activation without toxicity.



Favorable Pharmacokinetics

Cynomolgus monkey studies reveal **linear pharmacokinetic profiles** across the dose range of 0.2-20 mg/kg, with dose-dependent Cmax and drug exposure. This predictable PK profile supports straightforward clinical dose escalation and enables confident translation to human studies.

Accelerating Innovation to Improve Patients' Lives

Navika Bio connects groundbreaking biotech innovation with global pharmaceutical partners to deliver transformative therapies to patients worldwide.



Let's Connect

For more information about partnership opportunities and to join us on this exciting journey of bringing transformative therapies to patients worldwide, please reach out to:



Lawrence Hu, PhD

**Chief Technology Officer
Head of Business Development**

Phone: 973-967-9949

Email: lawrence@navikabio.com

